What kind of medicine is ivonib? What does it do?

Ivosidenib is a potent and selective inhibitor of isocitrate dehydrogenase-1 (IDH1) as monotherapy for patients aged ≥75 years or newly diagnosed AML who are not suitable for intensive induction chemotherapy. Ivonib in combination with azacitidine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia who are susceptible to IDH1 mutations who are ≥75 years of age or who are not suitable for intensive induction chemotherapy.

SusceptibilityIDH1mutations are defined as mutations that result in elevated levels of 2-hydroxyglutarate in leukemia cells, with efficacy predicted by clinically meaningful remission at recommended doses of ivosidenib or sustained inhibition of IDH1 mutational activity at recommended doses of ivosidenibconcentrations. Ivonibwith or without azacitidine is generally recommended as one of several options for the treatment of newly diagnosedAMLin older adults or adults with significant comorbidities.

500mg once daily. Continue treatment until disease progression or unacceptable toxicity occurs. Most patients achieve optimal response within 6 months after starting to take ivonib . Therefore, treatment should be continued for ≥6 months to allow time for response. On days 1-7( or days 1-5 and 8-9days), started on day 1 of cycle 1 combined application of ivonib and azacitidine75 mg/m2, divided or intravenous injection, once daily. Avonib produced in Laos costs about 5,000 to 6,000 yuan per box, and the price is favorable. If you want to get more high-quality information, you can contact Yaode . Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0